scholarly journals Downstream and into deep biology: Evolving business models in 'top tier' genomics companies

2006 ◽  
Vol 12 (2) ◽  
Author(s):  
Harry Rothman ◽  
Alison Kraft
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Drug Development ◽  
Business Models ◽  
Major Effect ◽  
Business Strategies ◽  
Fully Integrated ◽  
Biotechnology Firms ◽  
The Past

Genomics companies are changing their business models and some have moved beyond drug discovery into drug development. The authors' analysis of genomics companies' business models yields further insights into the widening role of genomics firms within drug innovation and on the evolving dynamics between the genomics sector and the wider pharmaceutical industry. Business models within the sector have included that of the FIPCO (Fully Integrated Pharmaceutical Company), technology and information platforms, and, more recently, a new 'dual' business model that combines established platform capabilities with drug development. The study identifies a cohort of 22 leading genomics companies and takes as its focus those companies following the dual and platform business strategies. The paper describes how, over the past five years, leading genomics companies have, typically, refocused their interests downstream within drug innovation, a move that brings new commercial opportunities but also threats. New and evolving business models are enabling these companies to leverage their commercial positions and capture value in the later stages of drug development. These shifts are characterised and the possibility that this 'downstream' trend could exert a major effect on the future relations between genomics companies and pharma/large biotechnology firms, and on drug innovation, is explored.

scholarly journals THE ROLE OF AGILE SOFTWARE ARCHITECT IN THE AGE OF DIGITAL DISRUPTION AND TRANSFORMATION

2020 ◽  
Vol 3 (2) ◽  
pp. 148-162
Author(s):  
Zoran Dragičević ◽  
Saša Bošnjak
Keyword(s):  
Empirical Research ◽  
Business Models ◽  
Business Strategies ◽  
Software Systems ◽  
Business Software ◽  
Digital Strategy ◽  
Platforms And Ecosystems ◽  
Digital Disruption ◽  
Agile Software

The consequence of the increasing development and use of digital technologies, in every segment of society, is the emergence of digital disruption - a powerful external pressure that is changing the way business is done in all industries. Businesses are responding to digital disruption by digital transformation, which involves organizational change, redefining and aligning digital and business strategies, new business models, increased agility of software development and delivery processes, migration and/or integration of legacy systems using cloud-based platforms and ecosystems. In such a context, one of the key responsibilities of a software architect is to maintain the agility of the organization by defending the flexibility of digital strategy and IT resources so that the enterprise is able to transform and respond adequately and rapidly to the effects of digital disruption. In this regard, the question arises as to how digital disruption and business transformation affect the change in the role, importance, competence and agility of a software architect, especially in the context of the development of complex business software systems. This paper aims to present the role of an agile software architect in the era of digital disruption and transformation, by integrating the results of theoretical and empirical research. A systematic literature review identifies the role, importance, and competencies of a software architect in implementing agile architecture. In other hand, empirical research, based on a case study in a large enterprise, provides a better understanding of the importance of software architect for aligning business and digital strategy, as well as its contribution to increasing the agility of the process of developing, delivering and integrating complex business software systems.

Drug Discovery

2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
New Approach ◽  
The Past ◽  
Scientific Exploration ◽  
Clinical Indications ◽  
The Future ◽  
Clinical Diagnoses

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.

Preservation and evolution: Local newspapers as ambidextrous organizations

Journalism ◽  
2020 ◽  
Vol 21 (4) ◽  
pp. 472-488 ◽  
Author(s):  
Joy Jenkins ◽  
Rasmus Kleis Nielsen
Keyword(s):  
Business Models ◽  
Business Strategies ◽  
Digital Environment ◽  
The Past ◽  
Local Newspapers ◽  
The United Kingdom ◽  
Regional Newspapers ◽  
News Organizations ◽  
Parent Companies ◽  
Depth Interviews

This study uses 48 in-depth interviews with managers, editors, and reporters at local and regional newspapers and their parent companies in four countries (Finland, France, Germany, and the United Kingdom) to examine how they discuss changes to their business models and the ways their news organizations are adapting to emerging audience-consumption trends in the digital environment. The results show that interviewees continue to prioritize the economic importance of their print products, despite declines in advertising and subscriptions. They also believe that for local news to continue, journalists must better understand the business strategies of their news organizations. Finally, they acknowledge the value of experimenting with new approaches to monetization, including implementing paywalls and using analytics to personalize content. In balancing the merits of their print products with their desire to develop new digital offerings, local newspapers seek to operate as ‘ambidextrous organizations’ that exploit the products of the past while exploring innovations that may help sustain them in the future.

Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004

2005 ◽  
Vol 11 (4) ◽  
Author(s):  
Mark J Belsey ◽  
Alex K Pavlou
Keyword(s):  
Drug Discovery ◽  
Early Stage ◽  
Target Identification ◽  
New Wave ◽  
Fully Integrated ◽  
Drug Discovery And Development ◽  
The Past ◽  
Initial Stage ◽  
Increasing Demand

As part of Datamonitor's alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and development collaborations between October 2002 and September 2004, which included 524 early-stage deals. Deal analysis shows that the leading pharma and biotech companies (fully integrated players) are the principal collaboration seekers, and that target and product innovation is driving the new wave of 21st century deals. These deals cover all phases of early-stage drug development, with lead product/target identification/validation accounting for the greatest proportion of collaborations. This represents a shift away from initial-stage collaborations, which are primarily focused on technologies such as genomics, as a result of the lack of tangible results that such technologies have delivered in the past. Following the continuously increasing demand for late-stage high-value products, the aim of the money and time invested in these early-stage collaborations is to reverse the pipeline productivity crisis currently affecting the industry's leaders over the mid to long term.

scholarly journals An expanding role for cell biologists in drug discovery and pharmacology

2012 ◽  
Vol 23 (21) ◽  
pp. 4162-4164 ◽  
Author(s):  
Peter K. Sorger ◽  
Birgit Schoeberl
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Drug Development ◽  
Basic Structure ◽  
Healthcare Systems ◽  
New Drugs ◽  
Conceptual Basis ◽  
The Face ◽  
Programming Skills ◽  
In Cells

The profound challenges facing clinicians, who must prescribe drugs in the face of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs despite ever-rising costs, represent opportunities for cell biologists interested in rethinking the conceptual basis of pharmacology and drug discovery. Much better understanding is required of the quantitative behaviors of networks targeted by drugs in cells, tissues, and organisms. Cell biologists interested in these topics should learn more about the basic structure of drug development campaigns and hone their quantitative and programming skills. A world of conceptual challenges and engaging industry–academic collaborations awaits, all with the promise of delivering real benefit to patients and strained healthcare systems.

Blockbuster Drugs

2014 ◽  
Author(s):  
Jie Jack Li
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
Business Models ◽  
Scientific Discovery ◽  
New Drugs ◽  
Pharmaceutical Companies ◽  
Blockbuster Drug ◽  
A Minor ◽  
Future Landscape

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

The importance of synthetic chemistry in the pharmaceutical industry

Science ◽  
2019 ◽  
Vol 363 (6424) ◽  
pp. eaat0805 ◽  
Author(s):  
Kevin R. Campos ◽  
Paul J. Coleman ◽  
Juan C. Alvarez ◽  
Spencer D. Dreher ◽  
Robert M. Garbaccio ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Synthetic Methods ◽  
Past Century ◽  
Synthetic Chemistry ◽  
Drug Discovery And Development ◽  
The Past ◽  
New Concepts ◽  
The Face ◽  
Chemical Matter

Innovations in synthetic chemistry have enabled the discovery of many breakthrough therapies that have improved human health over the past century. In the face of increasing challenges in the pharmaceutical sector, continued innovation in chemistry is required to drive the discovery of the next wave of medicines. Novel synthetic methods not only unlock access to previously unattainable chemical matter, but also inspire new concepts as to how we design and build chemical matter. We identify some of the most important recent advances in synthetic chemistry as well as opportunities at the interface with partner disciplines that are poised to transform the practice of drug discovery and development.

RETAIL COMPANY STRATEGY FACING INDUSTRIAL REVOLUTION 4.0

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Salihah Khairawati
Keyword(s):  
Business Models ◽  
Industrial Revolution ◽  
Business Environment ◽  
Business Strategies ◽  
Company Strategy ◽  
Retail Company ◽  
Online Shops ◽  
Role Of Information ◽  
Retail Shop

Facing changes in business environment, the companies should make adjustments in their operations. The role of information technology encourages everything in the internet (internet of things), which also has an impact on the retail industry. Retail companies improve themselves in facing changes in their industrial environment. The purpose of this article is to examine some retail businesses that have developed online shops in the current era and to formulate the retail company strategies to face the industrial revolution including redesigning business models and dynamic abilities, human resource readiness, developing features and shopping applications at retail shops and attractive promo offers for consumers. It is hoped that this study can provide input for retail shop managers in developing their business strategies

scholarly journals SMALL MOLECULES SOLVING BIG PROBLEMS: PRESENT AND FUTURE OF DRUG DISCOVERY

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Anna Lucia Fallacara ◽  
Iuni Margaret Laura Tris ◽  
Amalia Belfiore ◽  
Maurizio Botta
Keyword(s):  
Drug Discovery ◽  
Drug Development ◽  
Small Molecules ◽  
Rational Design ◽  
Development Process ◽  
New Drugs ◽  
Drug Development Process ◽  
Development Models ◽  
The Past ◽  
The Cost

The Drug development process has undergone a great change over the years. The way, from haphazard discovery of new natural products with a potent biological activity to a rational design of small molecule effective against a selected target, has been long and sprinkled with difficulties. The oldest drug development models are widely perceived as opaque and inefficient, with the cost of research and development continuing to rise even if the production of new drugs remains constant. The present paper, will give an overview of the principles, approaches, processes, and status of drug discovery today with an eye towards the past and the future.

Seizing Opportunities for Markets of Discovery: The Reconfigurations of Value Chains in Pharmaceutical Industry in the Global South

2018 ◽  
Vol 23 (3) ◽  
pp. 418-443
Author(s):  
Muriela Hinard De Pádua ◽  
Margarida Fontes ◽  
Cristina Sousa
Keyword(s):  
Drug Discovery ◽  
Drug Development ◽  
Value Chain ◽  
Potential Role ◽  
Learning Processes ◽  
Value Chains ◽  
Asian Countries ◽  
Non Local ◽  
Analyse Data

This article investigates whether Asian countries are becoming more active at the discovery stage, a higher stage of the drug development value chain. We conduct the first quantitative study to investigate these countries positioning in drug discovery activities. For this purpose, we draw on a database containing historical information on more than 61,000 drugs, for the period 1994–2015, and extract and analyse data on the drug discovery events in which a selected group of Asian countries were involved. The results show that these countries are increasingly involved in activities of discovery and that, in some of them, these activities are predominantly conducted on drugs owned by local organisations. Along with this process, markets for discovery are being created, both through sub-contracting and through partnerships among local organisations (for their own drugs) and between local and non-local ones. Second, drawing on the strategies and organisational set-ups adopted in each country, we distinguish a number of profiles regarding the ways competences for markets for discovery are being built. Third, we identify the existence of a strong regional centre of competences, acting as a local–global articulation locus for markets of discovery. These results provide new insights into the ways Asian countries are moving up the drug development value chain and contribute to our understanding of the learning processes underway in different contexts and the variety of configurations resulting from these processes, supporting a discussion on the potential role of policies to further expand markets for discovery.

Sign in / Sign up

Export Citation Format

Share Document